The healthcare industry segment focused on conducting diagnostic tests to detect infectious microorganisms in a patient's bloodstream. It aids in identifying bloodstream infections and sepsis. It includes various products and services used in hospitals and laboratories.

Blood Culture Tests Market by Method (Conventional, Automated), Product (Consumables, Instruments), Technology (Culture, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospitals, Reference Labs) & Region- Global Forecast to 2028

The global blood culture tests market is projected to reach USD 7.6 billion by 2028 from USD 5.2 billion in 2023, at a CAGR of 8.0%

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=159606753

Driver: Growing incidence of sepsis cases and high cost of treatment

Sepsis is a medical condition in which the body is prone to severe inflammatory responses to fungal and bacterial infections. Patients with chronic illness, implanted devices, and those with suppressed immune systems are more prone to growing sepsis.

Sepsis is considered a significant global socioeconomic burden as sepsis and septic shock are associated with a high morbidity rate (which may result in a prolonged hospital stay and increase the associated healthcare costs) and mortality rate. According to the Centre of Disease Control and Prevention (CDC), every year in the US, sepsis leads to more deaths than opioid overdoses, prostate cancer and breast cancer combined.

Restraint: Lack of trained laboratory technicians

Advancements in the technology in blood culture tests have increased their adoption among hospital and reference laboratories, which are major end users of these tests. Clinical guidelines and clinician education influence how diagnostic tests are incorporated into clinical practices. For providing improved patient care, it becomes necessary to engage a clinician’s expertise to determine the best diagnostic tests and interpret correct laboratory results. As the level of awareness about the latest technological advancements in blood culture tests is low among technicians (especially in emerging economies), the adoption of advanced technologies is restricted to a great extent. This is limiting the use of best diagnostic practices and restraining the greater uptake of technologically advanced products.

Market key Players

The prominent players in this market are Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), Anaerobe Systems, Inc. (US), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Iridica (US), Biosystems, Inc (US), BINDER GmBH (Germany), Terumo Corporation (Japan), Becton, Dickinson and Company (US), BioMérieux (France), Thermo Fisher Scientific Inc. (US), Danaher (US), Luminex Corporation (US), Bruker (US), Roche Diagnostics (Switzerland), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany) and Nikon Corporation (Japan).

Recent Developments

• In 2023, BioMérieux, announced that it has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for the VITEK REVEAL, formerly known as SPECIFIC REVEALRapid AST System. This rapid, modular, antimicrobial-susceptibility test platform that can deliver actionable results for Gram-negative bacteria directly from positive blood cultures in an average of five and a half hours1 enabling same-day treatment decision-making for patients suffering from bacteremia sepsis.
• In 2023, Bruker introduces fast next-generation MALDI Biotyper IVD Software. The MBT Compass HT IVD software provides a high sample throughput for microbial identification with time-to-result of ~5 minutes for 96 sample spots. Because of a fast sample target exchange, the MBT system can now analyze up to 600 samples per hour, while covering over 4,600 species in the reference library. 
• In 2022, BioMérieux, a world leader in the field of in vitro diagnostics, has entered into an agreement to acquire Specific Diagnostics, a privately held US based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. BioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021. With the addition of SPECIFIC REVEAL Rapid AST, the unique and comprehensive BioMérieux Sepsis Solution allows same-day AST results for Gram-negative bacteria to enable more targeted therapy and improve patient outcomes.
• In 2022, Beckman Coulter, partnered with Germany-based company Smart4Diagnostics to close the preanalytical data gap between blood collection and laboratory analysis due to errors that take place before the sample arrives in the laboratory, such as sample collection, patient identification, sample handling, sample transportation, sample loss, etc.
• In 2020, Becton, Dickinson and Company obtained the CE mark approval for the BD Vacutainer UltraTouch Push Button Blood Collection Set (BCS) with Preattached Holder. The one-handed safety activation of the push button allows clinicians to activate the safety mechanism while still attending to the patient and venipuncture site.

Report Objectives

• To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing the market growth
• To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To strategically analyze the market structure and profile the key players of the market and comprehensively analyze their core competencies
• To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East & Africa)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs.

Get 10% Free Customization on this Report-https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=159606753

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines — TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies -helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, and facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn, and Facebook.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1–888–600–6441

Email: sales@marketsandmarkets.com